Search

Your search keyword '"De Maeyer, G"' showing total 4 results
Start Over Author "De Maeyer, G"
4 results on '"De Maeyer, G"'

1. Reflective Practice in Urban Design

Author

Verbeke, J, Pak, B, De Maeyer, G, Montague, LM, Verbeke, J, Pak, B, De Maeyer, G, and Montague, LM

Abstract

This paper presents part of a PhD that explores the ways in which theories in urban design influence the process of urban design, and the extent to which they may inform design decisions. The focus of the paper is the empirical stage of the research; the execution of a site evaluation, urban design framework and masterplan design for Croydon in London, a commentary recording that process, and the subsequent analysis of it. Reflection on that process and product appears to indicate that theory’s influence in the creative process of urban design is distinctive but subservient to a variety of other influences. Apparently, the more conceptual and strategic the stage of design, the more extensive and explicit theory’s influence is. Conversely, the more spatial and detailed the stage of design, the more tacit and fragmented theory’s involvement seems to be. It is often implicit, embedded within the guiding principles that the individual designer exercises when generating and evaluating ideas, evidenced in the thought processes and decisions that are made.

Published
2013

2. Reflective Practice in Urban Design

Author

Montague, LM, Verbeke, J, Pak, B, and De Maeyer, G

Abstract

This paper presents part of a PhD that explores the ways in which theories in urban design influence the process of urban design, and the extent to which they may inform design decisions. The focus of the paper is the empirical stage of the research; the execution of a site evaluation, urban design framework and masterplan design for Croydon in London, a commentary recording that process, and the subsequent analysis of it. Reflection on that process and product appears to indicate that theory’s influence in the creative process of urban design is distinctive but subservient to a variety of other influences. Apparently, the more conceptual and strategic the stage of design, the more extensive and explicit theory’s influence is. Conversely, the more spatial and detailed the stage of design, the more tacit and fragmented theory’s involvement seems to be. It is often implicit, embedded within the guiding principles that the individual designer exercises when generating and evaluating ideas, evidenced in the thought processes and decisions that are made.

Published
2013

3. Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia .

Author

Davids MS, Kim HT, Yu L, De Maeyer G, McDonough M, Vartanov AR, Langey R, Fernandes SM, Hellman JM, Francoeur K, Arnason J, Jacobsen ED, LaCasce AS, Fisher DC, and Brown JR

Subjects
Alemtuzumab administration & dosage, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Combined Modality Therapy, Hematopoietic Stem Cell Transplantation adverse effects, Hematopoietic Stem Cell Transplantation methods, Humans, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Methylprednisolone administration & dosage, Prognosis, Transplantation, Homologous, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Chromosome Deletion, Chromosomes, Human, Pair 17, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Leukemia, Lymphocytic, Chronic, B-Cell therapy, Sequence Deletion, Tumor Suppressor Protein p53 genetics
Abstract

We hypothesized that ofatumumab with sequential methylprednisolone - alemtuzumab would be an effective and tolerable regimen for patients with high-risk chronic lymphocytic leukemia (CLL) with TP53 dysfunction. Thirty CLL patients with TP53 dysfunction (15 treatment naive (TN), 15 relapsed/refractory (R/R)) were enrolled in this phase II study. Therapy included ofatumumab with methylprednisolone for 2-4 monthly cycles, then ofatumumab with alemtuzumab for 4-24 weeks, then allogeneic transplantation or maintenance. The rate of overall response, complete response, marrow minimal residual disease (MRD) negativity, 3-year progression-free survival and overall survival were 80, 13, 80, 53, and 66%, respectively, in TN patients and 68, 0, 54, 25, and 53%, respectively, in R/R patients. Notable grade 3/4 toxicities included neutropenia and infection in 43 and 40% of patients, respectively. At median follow-up of 45 months, 13 patients died, and 10 patients are alive posttransplant. Overall, we observed high rates of MRD-negativity and acceptable tolerability in high-risk CLL.

Published
2019
Full Text
View/download PDF

4. On the diagnosis of erythrocyte enzyme defects in the presence of high reticulocyte counts.

Author

Lakomek M, Schröter W, De Maeyer G, and Winkler H

Subjects
Adult, Cell Separation methods, Erythrocyte Aging, Erythrocyte Count, Glucosephosphate Dehydrogenase blood, Hexokinase blood, Humans, Phosphofructokinase-1 blood, Pyruvate Kinase blood, Reticulocytes enzymology, Serologic Tests, Erythrocytes enzymology, Glucose-6-Phosphate Isomerase blood
Abstract

The separation of red blood cells into reticulocytes and young and old erythrocytes enables investigations of fractions with different contents of reticulocytes. Activities of hexokinase, glucose phosphate isomerase, phosphofructokinase, pyruvate kinase and glucose-6-phosphate dehydrogenase showed a linear relationship to reticulocyte counts. The dependence of these enzyme activities on the age of the red blood cells exhibited a strong decline from the reticulocyte to the young erythrocyte stage followed by only little further loss of activity, thus leading to a biphasic decay of enzyme activities. By linear regression analysis enzyme activities in erythrocytes (AE) and reticulocytes (AR) could be evaluated. The activity of a given enzyme in the reticulocyte exceeded that of the erythrocyte; the quotient AR/AE represents the decline of enzyme activity from the reticulocyte to the erythrocyte stage. This value AR/AE is 16.7 for pyruvate kinase and 9.4 for hexokinase and thus considerably higher than that for the other enzymes investigated (glucose phosphate isomerase: 2.9, phosphofructokinase: 4.3, glucose-6-phosphate dehydrogenase: 4.5). In patients suffering from erythrocyte enzymopathies, the AR/AE for pyruvate kinase was 16.2 and thus almost identical to the normal enzyme. Calibration curves where the enzyme activity is plotted versus the fraction of reticulocytes enable the determination of normal activity of a given erythrocyte enzyme depending on the content of reticulocytes in red blood cell suspensions. Thus an unambiguous diagnosis of enzyme defects irrespective of reticulocyte counts becomes possible.

Published
1989
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results